Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Gains from Investment Securities (2016 - 2021)

GT Biopharma (GTBP) has disclosed Gains from Investment Securities for 11 consecutive years, with -$25.9 million as the latest value for Q4 2021.

  • On a quarterly basis, Gains from Investment Securities fell 863100100.0% to -$25.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $138000.0, a 4599900.0% increase, with the full-year FY2024 number at -$12.9 million, down 168.77% from a year prior.
  • Gains from Investment Securities was -$25.9 million for Q4 2021 at GT Biopharma, down from $26.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $26.0 million in Q3 2021 to a low of -$25.9 million in Q4 2021.
  • A 5-year average of $116087.9 and a median of $1246.0 in 2017 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 145409.87% in 2019, then plummeted 863100100.0% in 2021.
  • GT Biopharma's Gains from Investment Securities stood at $1246.0 in 2017, then surged by 45.51% to $1813.1 in 2018, then crashed by 99.83% to $3.0 in 2019, then changed by 0.0% to $3.0 in 2020, then tumbled by 863100100.0% to -$25.9 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Gains from Investment Securities are -$25.9 million (Q4 2021), $26.0 million (Q3 2021), and $3.0 (Q4 2020).